






































Background: Neurogenic bladder sphincter dysfunction (NBSD) can develop as a result of a 
lesion at any level in the nervous system, including the cerebral cortex, spinal cord, or 
peripheral nervous system. Neurologic conditions in children leading to neurogenic bladder 
dysfunction are predominantly congenital neural tube defects (including myelomeningocele, 
lipomeningocele, sacral agenesis, and occult lesions causing tethered cord). Acquired causes 
such as spinal cord tumors or trauma or sequelae of transverse myelitis are less frequent. 
Whereas from an etiologic standpoint neurogenic bladder dysfunction is a heterogeneous 





























Medical management with CIC and anticholinergics is effective in preserving renal function 
and providing safe urinary continence in more than 90% of patients with a neurogenic 
bladder. Early diagnosis and treatment institution, long before continence becomes an issue at 
toddler age, can prevent both renal damage and secondary bladder-wall changes, thereby 
improving long-term outcomes. Augmentation cystoplasty is indicated where conservative 






Neurogenic bladder sphincter dysfunction (NBSD) can develop as a result of a lesion at any 
level in the nervous system, including the cerebral cortex, spinal cord, or peripheral nervous 
system. Neurologic conditions in children leading to neurogenic bladder dysfunction are 
predominantly congenital neural tube defects (including myelomeningocele, 
lipomeningocele, sacral agenesis, and occult lesions causing tethered cord). Acquired causes 
such as spinal cord tumors or trauma or sequelae of transverse myelitis are less frequent. 
Whereas from an etiologic standpoint neurogenic bladder dysfunction is a heterogeneous 
group, medical management will be similar irrespective of the underlying cause. The vast 
majority of knowledge about NBSD management comes from long-term experience with 
myelomeningocele (MMC), the most common neural tube defect. 
Following the institution of a general treatment policy with advances in neurosurgical and 
orthopedic treatments in previous decades, governing the associated NBSD has become 
crucial for improving quality of life and life expectancy in children with neural tube defects. 
In MMC patients, disordered innervation of the detrusor musculature and external sphincter 
adversely affects bladder function, which if untreated not only leads to incontinence but also 
will cause secondary damage and dysfunction of both the upper and lower urinary tracts. Key 
elements in optimal NBSD management are early diagnosis (including NBSD typology) and 
early (presymptomatic) institution of adequate medical treatment. There is indeed growing 
evidence that management decisions made during infancy, which prevent both renal damage 
and secondary bladder-wall changes, potentially impact long-term outcomes for renal 
































                                           REVIEW OF LITERATURE. 
Historical Evolution: 
The management of NBSD in children has undergone major changes over the years. A first 
milestone was the introduction of clean intermittent catheterization (CIC) in 1972 [1]. CIC 
(combined with anticholinergics if required) has made “conservative” (medical) management 
a successful treatment option, with a good outcome for quality of life and kidney protection. 
Further important breakthroughs were the wider application of urodynamic testing in the 
evaluation of infants and young children with suspected NBSD [2–4] and the better 
pathophysiological understanding of the natural history of NBSD in patients with spina 
bifida. In spina bifida, the natural history of the urinary tract in untreated NBSD is one of 
progressive deterioration by the age of 3 years in up to 58% of patients [5]. Several reports 
have shown this deterioration to be directly related to increased intravesical pressure. In 
1981, the bladder pressure at which urethral leakage occurred was found to be a useful 
predictor of unsafe bladder function [2]. The leak-point pressure, as it is now commonly 
referred to, has become accepted as one of the urodynamic parameters that allows clinicians 
to differentiate patients with relatively low or high risk for subsequent upper urinary tract 
deterioration. In 1984, detrusor external sphincter dyssynergia (DSD) was identified as an 
important factor leading to functional obstruction, and intravesical pressure was recognized 
as the pathophysiological mechanism of subsequent upper urinary tract deterioration [3]. 
Shortly thereafter, urodynamics in infants and children was shown to allow a functional 
classification of NBSD that correlated with clinical entities of incontinence and obstruction, 
an approach that has allowed the concept of individualized and presymptomatic therapy in 






Normal voiding essentially is a spinal reflex that is modulated by the central nervous system (brain 
and spinal cord), which coordinates the functions of the bladder and urethra. The bladder and urethra 
are innervated by 3 sets of peripheral nerves arising from the autonomic nervous system (ANS) and 
somatic nervous system. The central nervous system is composed of the brain, brain stem, and the 
spinal cord.  
Brain 
The brain is the master control of the entire urinary system. 
The micturition control center is located in the frontal lobe of the brain. The primary activity of this 
area is to send tonically inhibitory signals to the detrusor muscle to prevent the bladder from emptying 
(contracting) until a socially acceptable time and place to urinate is available. 
The signal transmitted by the brain is routed through 2 intermediate stops (the brainstem and the 
sacral spinal cord) prior to reaching the bladder. 
Brainstem 
The brainstem is located at the base of the skull. Within the brainstem is a specialized area known as 
the pons, a major relay center between the brain and the bladder. The pons is responsible for 
coordinating the activities of the urinary sphincters and the bladder so that they work in synergy. The 
mechanical process of urination is coordinated by the pons in the area known as the pontine 
micturition center (PMC). The PMC coordinates the urethral sphincter relaxation and detrusor 
contraction to facilitate urination. The conscious sensations associated with bladder activity are 
transmitted to the pons from the cerebral cortex. The interaction of a variety of excitatory and 
inhibitory neuronal systems is the function of the PMC, which is characterized by its inborn excitatory 
nature. The PMC functions as a relay switch in the voiding pathway. Stimulation of the PMC causes 
the urethral sphincters to open while facilitating the detrusor to contract and expel the urine. 
The PMC is affected by emotions, which is why some people may experience incontinence when they 
are excited or scared. The ability of the brain to control the PMC is part of the social training that 
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children experience during growth and development. Usually the brain takes over the control of the 
pons at age 3-4 years, which is why most children undergo toilet training at this age. 
When the bladder becomes full, the stretch receptors of the detrusor muscle send a signal to the 
pons, which in turn notifies the brain. People perceive this signal (bladder fullness) as a sudden desire 
to go to the bathroom. Under normal situations, the brain sends an inhibitory signal to the pons to 
inhibit the bladder from contracting until a bathroom is found. 
When the PMC is deactivated, the urge to urinate disappears, allowing the patient to delay urination 
until finding a socially acceptable time and place. When urination is appropriate, the brain sends 
excitatory signals to the pons, allowing the urinary sphincters to open and the detrusor to empty. 
Spinal cord 
The spinal cord extends from the brainstem down to the lumbosacral spine. It is located in the spinal 
canal and is protected by the cerebrospinal fluid, meninges, and a vertebral column. It is 
approximately 14 inches long in an adult. Along its course, the spinal cord sprouts off many nerve 
branches to different parts of the body. 
The spinal cord functions as a long communication pathway between the brainstem and the sacral 
spinal cord. When the sacral cord receives the sensory information from the bladder, this signal 
travels up the spinal cord to the pons and then ultimately to the brain. The brain interprets this signal 
and sends a reply via the pons that travels down the spinal cord to the sacral cord and, subsequently, 
to the bladder. 
In the normal cycle of bladder filling and emptying, the spinal cord acts as an important intermediary 
between the pons and the sacral cord. An intact spinal cord is critical for normal micturition. 
If spinal cord injury has occurred, the patient will demonstrate symptoms of urinary frequency, 
urgency, and urge incontinence but will be unable to empty his or her bladder completely. This occurs 
because the urinary bladder and the sphincter are both overactive, a condition termed detrusor 
sphincter dyssynergia with detrusor hyperreflexia (DSD-DH). 
The sacral spinal cord is the terminal portion of the spinal cord situated at the lower back in the 
lumbar area. This is a specialized area of the spinal cord known as the sacral reflex center. It is 
responsible for bladder contractions. The sacral reflex center is the primitive voiding center. 
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In infants, the higher center of voiding control (the brain) is not mature enough to command the 
bladder, which is why control of urination in infants and young children comes from signals sent from 
the sacral cord. When urine fills the infant bladder, an excitatory signal is sent to the sacral cord. 
When this signal is received by the sacral cord, the spinal reflex center automatically triggers the 
detrusor to contract. The result is involuntary detrusor contractions with coordinated voiding. 
A continuous cycle of bladder filling and emptying occurs, which is why infants and young children are 
dependent on diapers until they are toilet trained. As the child's brain matures and develops, it 
gradually dominates the control of the bladder and the urinary sphincters to inhibit involuntary voiding 
until complete control is attained. Voluntary continence usually is attained by age 3-4 years. By this 
time, control of the voiding process has been relinquished by the sacral reflex center of the sacral 
cord to the higher center in the brain. 
If the sacral cord becomes severely injured (eg, spinal tumor, herniated disc), the bladder may not 
function. Affected patients may develop urinary retention, termed detrusor areflexia. The detrusor will 
be unable to contract, so the patient will not be able to urinate and urinary retention will occur. 
Peripheral nerves 
Peripheral nerves form an intricate network of pathways for sending and receiving information 
throughout the body. The nerves originate from the main trunk of the spinal cord and branch out in 
different directions to cover the entire body. Nerves convert the internal and external environmental 
stimuli to electrical signals so that the human body can understand stimuli as one of the ordinary 
senses (ie, hearing, sight, smell, touch, taste, equilibrium). The bladder and the urethral sphincters 
are under the influence of their corresponding nerves. 
The ANS lies outside of the central nervous system. It regulates the actions of the internal organs (eg, 
intestines, heart, bladder) under involuntary control. The ANS is divided into the sympathetic and the 
parasympathetic nervous system. 
Under normal conditions, the bladder and the internal urethral sphincter primarily are under 
sympathetic nervous system control. When the sympathetic nervous system is active, it causes the 
bladder to increase its capacity without increasing detrusor resting pressure (accommodation) and 
stimulates the internal urinary sphincter to remain tightly closed. The sympathetic activity also inhibits 
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parasympathetic stimulation. When the sympathetic nervous system is active, urinary accommodation 
occurs and the micturition reflex is inhibited. 
 
The parasympathetic nervous system functions in a manner opposite to that of the sympathetic 
nervous system. In terms of urinary function, the parasympathetic nerves stimulate the detrusor to 
contract. Immediately preceding parasympathetic stimulation, the sympathetic influence on the 
internal urethral sphincter becomes suppressed so that the internal sphincter relaxes and opens. In 
addition, the activity of the pudendal nerve is inhibited to cause the external sphincter to open. The 
result is facilitation of voluntary urination. 
 
Like the ANS, the somatic nervous system is a part of the nervous system that lies outside of the 
central spinal cord. The somatic nervous system regulates the actions of the muscles under voluntary 
control. Examples of these muscles are the external urinary sphincter and the pelvic diaphragm. The 
pudendal nerve originates from the nucleus of Onuf and regulates the voluntary actions of the 
external urinary sphincter and the pelvic diaphragm. Activation of the pudendal nerve causes 
contraction of the external sphincter and the pelvic floor muscles, which occurs with activities such as 
Kegel exercises. Difficult or prolonged vaginal delivery may cause temporary neurapraxia of the 
pudendal nerve and cause stress urinary incontinence. Conversely, suprasacral-infrapontine spinal 










Under normal conditions, the detrusor muscle, bladder neck, and striated external sphincter 
function as a synergistic unit for adequate storage and complete evacuation of urine. In 
healthy bladders, the change in bladder-filling pressure between empty and full is normally 
less than 10–15 cm H2O. Normal voiding pressures for males and females are from 50 to 
80 cm H2O and from 40 to 65 cm H2O, respectively [7]. 
In patients with NBSD, disordered innervation of the detrusor musculature and external 
sphincter adversely affects bladder function. In recent years, it has become clear that children 
with this condition can be categorized into high- and low-risk groups for secondary damage 
from a neurogenic bladder based on intravesical pressure. When the detrusor (filling) 
pressure exceeds 40 cm H2O, glomerular filtration rate decreases and pyelocaliceal and 
ureteral drainage deteriorates, leading to obstructive hydronephrosis and/or vesicoureteral 
reflux [2, 8–10]. Even in the absence of reflux or upper urinary tract dilatation, high 
intravesical pressure can impair drainage of urine into the bladder. Any pathophysiologic 
process that causes either intermittent or continuous elevation of bladder pressure above 
40 cm H2O places the child at risk for upper urinary tract dysfunction, urinary tract 
infections, and ultimately renal failure. Intermittent elevation of bladder pressure may occur 
from detrusor hypertonia, hyperreflexia, or both. Hyperreflexia may cause intermittent 
elevation of bladder pressure, especially if the external sphincter acts reflexively and tightens 
rather than relaxes in an attempt to prevent micturition [detrusor sphincter dyssynergia 
(DSD)]. Over a long period of time, hyperreflexia with pressures greater than 40 cm H2O 
may result in detrusor decompensation (areflexia from myogenic failure) or in detrusor 
hypertrophy with associated sacculations and subsequent diverticula formation. These 
pathophysiologic changes affect the elastic and vesicoelastic properties of the bladder and 
also result in mechanical ureterovesical junction obstruction. Continuous elevation of bladder 
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pressure above 40 cm H2O may occur from a hypertonic detrusor or a hypertrophic small-
capacity bladder secondary to outflow obstruction [11]. Bladder outlet obstruction is caused 
by DSD, or by fibrosis of the external urethral sphincter secondary to partial or complete 
denervation [3, 12, 13]. Bladder outlet obstruction will lead to elevated (pathologic) voiding 
pressures, which will contribute to either detrusor decompensation or hypertrophy. Finally, 
recurrent urinary tract infections due to bladder residue may aggravate damage to the 
neurogenic bladder through processes of transmural inflammation and fibrosis. Together with 
high intravesical pressures and/or vesicoureteral reflux, these lower urinary tract infections 



















General principles and treatment goals 
The cornerstone of optimal NBSD management is early identification and characterization 
(typology) and the institution of proactive therapy. Crucial for long-term prognosis of 
patients with NBSD is the fact that the management must start before consequences of 
bladder dysfunction become apparent. From the outset, the goals of management are to 
prevent or minimize secondary damage to the upper urinary tracts and bladder from the 
primary neurogenic bladder dysfunction and to achieve safe social continence [14]. Thus, 
long before continence becomes an issue, starting from the first year of life, management is 
directed at creating a low-pressure reservoir and ensuring complete and safe bladder 
emptying. 
Clean intermittent catheterization (CIC) or self-catheterization (CISC) in combination with 
anticholinergics (oxybutynin) is the standard therapy for children with neurogenic bladder 
dysfunction with detrusor hyperactivity and/or DSD [11, 15, 16]. This treatment is also 
feasible and effective in developing countries, where untreated neuropathic bladder is an 
important cause of preventable chronic renal failure [17, 18]. CIC enables complete bladder 
emptying and thus avoids bladder residues and consequent risks for infections. In the high-
risk bladder with DSD, CIC also allows bladder emptying before the occurrence of otherwise 
“spontaneous” high-pressure voiding, which is known to be detrimental for kidney function 
and drainage. Oxybutynin, a bladder smooth-muscle relaxant, is used to improve bladder 
dynamics through suppression of detrusor hypertonicity and hyperreflexia. By doing so, 
oxybutynin eliminates (high-pressure) uninhibited detrusor contractions (and thus urinary 
leakage) and prevents high-pressure bladder storage (due to detrusor hypertonicity or low 




Early management, including diagnosis and identification of the high-risk 
bladder 
At birth, the majority of patients with neurogenic bladder has normal upper urinary tracts. 
Without proper management, urinary tract infections and elevated bladder pressures with 
secondary bladder-wall changes may cause upper urinary tract deterioration within 3 years in 
up to 58% [5]. One third of children who develop impaired kidney drainage do so within the 
first year of life [19]. The specific abnormalities vary considerably and are not predicted by 
the level of the spinal cord defect. Furthermore, the dysfunctional pattern may be dynamic, 
influenced by spinal cord surgery, tethering, and denervation. In the initial baseline 
evaluation, clinical observations must be completed with urinalysis (microscopy and culture), 
renal/bladder ultrasound, and cystourethrogram. These allow the experienced clinician to 
suspect the type of NBSD and to identify the high-risk subgroup. The next consideration is 
when to perform urodynamic studies. 
Two different opinions exist in the literature on the use of urodynamic studies in the early 
evaluation and further follow-up. In one approach, urodynamic assessment has become an 
integral part of the initial evaluation and subsequent management, as it allows recognition of 
the different subtypes of NBSD (typology), proactive interventions, evaluation and guidance 
of therapy, and early detection of neurologic deterioration (such as symptomatic tethering of 
the spinal cord [20]). Advocates justify this approach of routine urodynamics to minimize the 
deleterious effects of high intravesical pressure by directly measuring it rather than indirectly 
suspecting it from the development of upper and lower urinary tract changes on serial 
radiologic imaging. Several studies have shown that early urodynamic evaluation of children 
with NBSD allows the prediction of which newborns are at risk for upper urinary tract 
deterioration. Urodynamic risk factors are low bladder compliance, intravesical pressure 
more than 40 cm H2O, and DSD [2, 3, 6, 21]. The alternative to urodynamic-based 
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management is serial radiologic imaging to detect secondary evidence of high bladder 
pressure. Critics of newborn and early infancy urodynamics refer to a lack of standards for 
performance and interpretation, which might lead to unnecessary interventions [22, 23]. 
Those authors recommend careful history, physical examination, upper urinary tract imaging, 
and close follow-up during infancy and childhood, reserving urodynamic studies only for 
patients with evidence of urinary retention on physical examination, new-onset 
hydronephrosis or febrile urinary tract infection, or for evaluation to achieve continence. 
Proponents of this approach with selective urodynamics suggest that close monitoring with 
prompt intervention at first signs of deterioration is effective in protecting the upper urinary 
tracts (including preservation of nephrons and thus renal function in the long run). A 
remaining concern, however, could be that in this more expectant approach, high intravesical 
pressures may have already resulted in irreversible and avoidable damage to the bladder wall, 
resulting in small-capacity, low-compliance bladders later in life. 
Although many questions regarding optimal evaluation and management remain unanswered, 
the consensus on the need of close surveillance, especially in the first years of life, plus the 
possibility that proactive treatment may be better for the bladder in the very long term, 
emphasize the need for an integrated approach in which clinical observations, serial imaging, 
and urodynamics are the basis for early adequate treatment. 
Urodynamic studies: special considerations in children with NBSD 
If properly performed, even with possible shortcomings in newborns and infancy, 
urodynamic studies allow direct diagnosis of NBSD and recognition of dysfunction subtypes. 
This functional classification allows adequate treatment for the different types and early 
proactive treatment for the bladder at risk [6]. 
It is important for the practitioner to understand the complexities involved in performing 
urodynamic studies in newborns, infants, and children. Urodynamic assessment can provide 
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reproducible results in newborns and infants, but it requires attention to mechanical factors 
and filling rates. The younger the child, the higher the risk that mechanical factors (such as 
bladder-outlet obstruction by the catheter used for the investigation) may produce artificial 
information (elevated leak pressure or inability to void). It has also been shown that using a 
bladder infusion rate as close as possible to the natural filling rate is important for correct 
assessment of detrusor properties [24]. It is presumed that fast infusion rates overcome 
vesicoelastic detrusor properties, falsely indicating detrusor hypertonicity [11]. On the other 
hand, in children who have apparent low-pressure cystograms and who leak during filling 
(due to sphincter hypoactivity), detrusor hypertonia may be unrecognized [25]. In these 
children, it is important to perform a provocative study (including bladder neck occlusion 
with a balloon catheter) to identify unrecognized detrusor hyperactivity prior to bladder-neck 
surgery for treatment of incontinence. Electromyographic (EMG) evaluation of the external 
urethral sphincter is required to identify DSD. The use of concentric EMG needles is 
preferred, as it gives more reliable information than patch electrodes [11]. The combination 
of X-ray cystography with cystometrogram and sphincter EMG (video urodynamics) allows 
accurate evaluation of the link between intravesical pressure and vesicoureteral reflux and 
gives direct visual information of (dys)synergia between detrusor and sphincter mechanisms 
[26]. 
Clean intermittent catheterisation 
In children with neurogenic bladder, CIC is the first-choice treatment to empty the bladder 
adequately (no residue, no infection) and safely (prior to high-pressure voiding), and it is a 
valuable tool for achieving continence. The wide variety of used materials and techniques for 
CIC does not seem to affect efficacy and safety as long as some basic principles are applied: 
proper education and training, clean and atraumatic application, and achievement of good 
patient compliance on a long-term basis. For education, training, and further guidance during 
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follow-up, a dedicated continence nurse is invaluable. Patients and caregivers must 
understand what is wrong with the bladder/sphincter and why CIC is proposed for treatment, 
and they have to learn how to catheterize properly. CIC has been successfully used by parents 
even in newborns and infants, becoming a part of their everyday routine [27]. Some authors 
prefer early institution of CIC in all infants with NBSD, given the fact that by the age of 
3 years, CIC will be required in all for achieving continence, and given the difficulties of 
starting CIC at toddler age [28]. Such early institution of CIC seems to improve family 
compliance and their ability to assist the child in coping with their disease and with CIC [29]. 
CISC can be successfully taught to boys and girls who are motivated and who have 
developed the required dexterity, mostly around the age of 6 years. The required frequency of 
catheterization depends on several factors: fluid intake, bladder capacity, and bladder 
filling/voiding pressures. In practice, it is recommended to catheterize six times a day in 
infants (linked with feeding time) and five times a day in school-aged children. Although 
reported incidences of CIC-related infection risks are variable, it is generally agreed that the 
risk is low as long as complete bladder emptying is achieved. Furthermore, reused supplies 
are not related to more urinary tract infections [30]. If symptomatic infections occur, these are 
mainly caused by incomplete bladder emptying, and CIC appliance by child or caregiver 
needs to be optimized. To prevent urethral strictures and false passage in boys, catheter 
lubrication and avoidance of forceful manipulation during catheter insertion are advocated. 
Nonreusable low-friction catheters are considered valuable in high-risk male patients with 
urethral false passage or very tense sphincters but are unnecessary in routine cases [31]. To 
maintain therapeutic compliance with CISC in adolescents, psychosocial support is often 
required. Neurogenic bowel dysfunction with constipation and fecal soiling can interfere with 
the institution of a successful CIC treatment. Retained stools may mechanically impair 
bladder filling, increase detrusor irritability, or contribute to urine retention. Stool 
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incontinence increases the risk of bladder contamination and urinary tract infection. An 
effective bowel management program is therefore needed. Finally, given the high prevalence 
of latex allergy [32], in the spina bifida population, a strict latex-free approach is of extreme 
importance. 
Pharmacologic treatment: anticholinergics 
Of the anticholinergic agents available, oxybutynin hydrochloride is most commonly used, 
and long-term experience supports its safety also in newborns and infants [33]. Oxybutynin is 
a tertiary amine with a well-documented therapeutic effect on detrusor hyperactivity, and its 
effectiveness is attributed to a combination of anticholinergic (M3-selective receptor subtype 
antagonism), antispasmodic, local anesthetic and calcium-channel-blocking activity [34]. 
Several studies have shown its efficacy for decreasing the filling pressure, increasing the 
capacity of the neurogenic bladder, and preserving renal function [35–37]. The usual dose 
regimen of oral oxybutynin is 0.3–0.6 mg/kg per day in three doses. 
In children with insufficient response or significant systemic side effects to oral oxybutynin, 
intravesical instillation of oxybutynin has been shown to be a highly efficacious, reliable, and 
well-tolerated therapy for children who would otherwise require surgical therapy [38–43]. 
Because a solution suitable for intravesical instillation was not available, crushed oxybutynin 
tablets were used in the earlier trials, with consequent problems of inconvenience and 
impracticability, and it was the belief of several authors that poor patient compliance could be 
resolved by an optimized drug preparation [40, 44]. It was subsequently shown that, indeed, 
eliminating the complex crushing preparation by child or parent makes intravesical 
oxybutynin therapy easy to use and acceptable for long-term therapy [41]. 
The mechanisms underlying the more potent and longer-acting detrusor-suppressive effects 
of intravesical oxybutyinin, as well as its better tolerability, have been investigated by several 
groups. It was demonstrated that a reduced first-pass metabolism of oxybutynin after 
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intravesical instillation, resulting in a reduced generation of the N-desethyl metabolite, may 
explain the clinically relevant reduction of systemic side effects that characterizes intravesical 
compared with oral oxybutynin therapy [45]. In addition, these pharmacokinetic studies 
provided first evidence for a direct local rather than a systemic effect of intravesical 
oxybutynin on detrusor muscle [45]. Further evidence for a local effect of intravesically 
administered oxybutynin was provided by studies showing local (urothelial) accumulation, 
suppression of muscarinic receptor-mediated detrusor muscle contractions, and blocking of 
muscarinic receptors in bladder-afferent pathways [46, 47]. In most reports, intravesical 
oxybutynin is used in dosages between 0.3 and 0.6 mg/kg per day in two or three doses. 
Given its better tolerability compared with oral treatment, if required, intravesical dosages 
can be further increased up to doses of 0.9 mg/kg per day [43]. 
To date, the vast majority (~ 90%) of patients can be treated successfully with the gold 
standard treatment of oxybutynin (oral or intravesical) and CIC. Other bladder-relaxant drugs 
include propiverine (10–15 mg b.i.d. or t.i.d., adult dose), trospium (20 mg b.i.d., adult dose), 
extended-release oxybutynin, and tolterodine (children 0.25–1 mg b.i.d., adults 1–2 mg 
b.i.d.). The current experience with compounds other than oxybutynin is still limited in 
children with neurogenic bladder [48, 49]. Botulinum A toxin injections into the detrusor 
muscle have been shown to be a potentially valuable approach in the neurogenic overactive 
bladder [50]. Repeated botulinum A toxin injections (as an alternative for or an additive to 
anticholinergics) could be considered to postpone or avoid surgical procedures in the small 
minority of children not responding to standard therapy with CIC and anticholinergics [51]. 
However, further investigations are required, given remaining concerns about costs and long-
term efficacy and safety of prolonged botulinum A toxin administration. Although some 
authors have advocated alfa-receptor stimulation of the bladder neck, no validated medical 
treatment is available to enhance the bladder outlet. 
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Medical management of NBSD in clinical practice 
Optimal management involves first, early diagnosis, including recognition of high-risk 
subtypes, and second, proactive institution of adequate treatment. Early proactive treatment 
of high-pressure dyssynergic lower urinary tracts is important in the long term, not only to 
preserve renal function [52] but also to prevent poor bladder compliance and the subsequent 
need for bladder augmentation [35]. Urodynamic assessment is used in newborns and infants 
to come to a functional classification of NBSD, allowing presymptomatic interventions in the 
high-risk groups and individualized treatment planning according to the type of dysfunction 
[6, 29, 53]. 
In clinical practice, four major subtypes can be used to describe NBSD : Sphincter 
overactivity combined with detrusor underactivity (type A) or overactivity (type B), and 
sphincter underactivity combined with detrusor underactivity (type C) or with detrusor 
overactivity (type D). The easiest type to treat is type A. This bladder type requires early 
treatment because of urine retention with high filling pressure and continuous leaking. Here, 
CIC alone is effective and sufficient and will make the bladder safe and infection free, and 
the patient will be dry in between (social continence). Good care to empty the bladder totally 
is most important to avoid bladder infections caused by residual urine. Dysfunctional type B 
will have high filling and high voiding pressures, being very unsafe from birth onward due to 
DSD. Here, the act of voiding has to be prevented. With oxybutynin, the overactive detrusor 
can be “pharmacologically converted” to an inactive reservoir (situation similar to type A), 
which has to be emptied with CIC. In type C, CIC reduces the degree of incontinence and 
offers much better control over urinary tract infections. To achieve continence, this type will 
at a later age need surgical intervention on the sphincter (e.g. sling operation). An important 
caveat here is that detrusor instability may emerge only after surgical improvement of outlet 
resistance. If this detrusor instability would remain unrecognized and untreated (with 
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oxybutynin), bladder-outlet surgery would have converted a “wet but safe” into a “dry but 
unsafe” bladder. In the last dysfunctional subtype (type D), the bladder leaks due to detrusor 
instability and gradually becomes unsafe due to secondary bladder-wall changes with 
detrusor hypertrophy and loss of bladder compliance. Therefore, treatment consists of CIC 






Once appropriate therapy has been initiated, adequate follow-up is required, with adjustments 
if needed (CIC frequency, medication dosing and administration route). Treatment efficacy 
can be assessed using clinical parameters (including CIC frequency and volume charts), 
urinalysis, renal and bladder ultrasound, X-ray cystography, and video urodynamics. 
As long-term sequelae of insufficiently treated neurogenic bladders (renal scarring, 
noncompliant fibrotic bladder) already have their origin in the first years of life, the 
frequency of multidisciplinary follow-up visits must be age dependent (3× yearly up to age 
3 years, 2× yearly in school-aged children, yearly in adults). Typically, urinalysis and 
ultrasound are performed at all visits, cystography to investigate unexpected upper urinary 
tract infections, and urodynamics periodically to verify that under treatment, the catheterized 
bladder volumes are age appropriate [54] and stored under safe pressure conditions (storage 
of expected bladder capacity at pressures below 30 cm H2O; see [55]). 
With early instituted and optimal treatment, the large majority of patients can be adequately 
controlled without antireflux surgery or surgical bladder augmentation . Augmentation 
cystoplasty is limited to a small group of patients in whom medical treatment fails 
(persistence of high filling pressures). In patients with insufficient sphincter activity, 
continence achievement will require bladder-outlet surgery in addition to medical treatment. 
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Long-term outcome evaluation and need for life-long follow-up 
Lifelong follow-up with further periodic investigations of upper urinary tract changes, renal 
function, and bladder status is extremely important. There are two reasons why long-term 
outcome evaluation in adulthood and life-long patient follow-up are indispensable. First, for 
the individual patient, therapy is a life-long requisite, and verifying preservation of the 
patient’s kidneys is only possible by repetitive assessment throughout adolescence and 
adulthood. Second, in general, detailed long-term follow-up data will show whether a 
treatment policy driven by long-term goals is sufficiently effective or requires further 
adaptations. The effectiveness of efforts preserving upper urinary tract function can only be 
judged by assessing the ultimate outcome once these patients have reached adolescence or 
adulthood [29]. In populations with NBSD, no consensus exists as to how renal status is 
ideally evaluated [56]. In clinical practice, upper urinary tract deterioration or protection is 
often monitored by radiographic images of hydronephrosis and vesicoureteral reflux. 
Modalities used to look at renal functions include nuclear imaging [dimercaptosuccinate acid 
(DMSA) renal scan], urinary concentrating ability, and glomerular filtration rate assessment. 
For the latter, creatinine (Cr) clearance can be used for patients who are socially continent; 
for others, inulin or Cr ethylenediaminetetraacetate (EDTA) clearance can be used. Which 




















































































































































































































































































































































































































Normal  14  5  0  0  1 
Mild HUN  6  0  1  3  0 
Moderate HUN  16  3 1 1 1 




















































































































































































































































































































































































































































































































































Clean intermittent catheterization (CIC) or self-catheterization (CISC) in combination with 
anticholinergics (oxybutynin) is the standard therapy for children with neurogenic bladder 
dysfunction with detrusor hyperactivity and/or DSD [11, 15, 16]. This treatment is also 
feasible and effective in developing countries, where untreated neuropathic bladder is an 
important cause of preventable chronic renal failure [17, 18]. CIC enables complete bladder 
emptying and thus avoids bladder residues and consequent risks for infections. In the high-
risk bladder with DSD, CIC also allows bladder emptying before the occurrence of otherwise 
“spontaneous” high-pressure voiding, which is known to be detrimental for kidney function 
and drainage. Oxybutynin, a bladder smooth-muscle relaxant, is used to improve bladder 
dynamics through suppression of detrusor hypertonicity and hyperreflexia. By doing so, 
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oxybutynin eliminates (high-pressure) uninhibited detrusor contractions (and thus urinary 
leakage) and prevents high-pressure bladder storage (due to detrusor hypertonicity) 
At birth, the majority of patients with neurogenic bladder has normal upper urinary tracts. 
Without proper management, urinary tract infections and elevated bladder pressures with 
secondary bladder-wall changes may cause upper urinary tract deterioration within 3 years in 
up to 58% [5]. One third of children who develop impaired kidney drainage do so within the 
first year of life [19]. The specific abnormalities vary considerably and are not predicted by 
the level of the spinal cord defect. Furthermore, the dysfunctional pattern may be dynamic, 









































Medical management with CIC and anticholinergics is effective in preserving renal function 
and providing safe urinary continence in more than 90% of patients with a neurogenic 
bladder. Early diagnosis and treatment institution, long before continence becomes an issue at 
toddler age, can prevent both renal damage and secondary bladder-wall changes, thereby 
improving long-term outcomes. Augmentation cystoplasty is indicated where conservative 
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neurogenic bladder sphincter dysfunction
MMC Myelomeningocele 
CIC clean intermittent catheterization 
CISC clean intermittent self-catheterization 
DSD detrusor sphincter dyssynergia 










































Name Hosp No Age 1  Age 2 Sex UTI crea1 crea2 USG 1 USG 2 MCU 1 MCU2 Treatment F/U (yrs) Etiology
Sakiya 352042c 6 9 F P 0.5 0.6 N N Nil ‐ C+O 3 MMC
Goutham 330958c 1 ‐ M A ‐ ‐ N ‐ L I ‐ C+O ‐ MMC
Gokul Raj 300290c 6 ‐ M P 0.5 ‐ N ‐ L I ‐ C+O ‐ MMC
Suguna' B 094822C 2 4 F P 0.9 0.7 B/L mild B/L mild R IV, L I ‐ C+O 2 MMC
Amit Dey 488585C 12 ‐ M A 0.7 ‐ B/L gross ‐ L V ‐ Aug ‐ MMC
Blesson 398717C 4 ‐ M A 0.5 ‐ ‐ ‐ B/L V ‐ Aug ‐ MMC
Chintu P 509926C 13 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
G. Begum's B 652058B 6 11 M A 0.5 0.5 B/L mild N Nil ‐ C+O 5 MMC
Jitendra Shaw 439332C 14 ‐ M A 0.8 ‐ N ‐ L I ‐ C+O ‐ MMC
Malathi 505178C 3 ‐ F A 0.4 ‐ N ‐ Nil ‐ C+O ‐ MMC
Nithin 461777C 3 8 M P 0.5 0.5 N N Nil ‐ C+O 5 MMC
Nandalal 535507C 9 15 M A 0.5 0,5 N N Nil ‐ C+O 6 MMC
Palani 385938A 14 20 M A 1.1 1 N N Nil ‐ Aug 6 MMC
Puja Barui 529044C 5 6 F A 1.3 1.1 B/L mod B/L mild L V Nil Aug, L →R TUU 1 MMC
Prabavathi's B 235725C 2 8 M A 0.6 0.7 N N R III, L I Nil Aug+ BND 6 MMC
Rangasusma 460647C 4 8 F P 0.5 0.6 B/L mild B/L mild Nil ‐ Aug 4 MMC
Srinivasan 457827C 14 15 M A 0.7 0.9 N ‐ Nil ‐ C+O 1 MMC
Syam Prakash 459487C 4 7 M P 0.4 0.5 B/L mild  N R V, L IINil Aug 3 MMC
Sophia 51979C 2 4 F A 1.1 0.6 L mod L mild L IV Nil Aug+L reimplant2 MMC
Saptharishi 522954B 7 ‐ M A 0.6 ‐ N ‐ Nil ‐ C+O ‐ MMC
Suguna' B 094822C 3 4 F P 0.7 0.7 B/L mild B/L mild R IV, L I ‐ Aug 1 MMC
Sahaya Ruben 415226C 11 15 M A 0.7 0.9 B/L mod B/L mod R III, LVNil Aug+ B/L reimpl 4 MMC
Vishnupriya 466059C 8 ‐ F A 0.4 ‐ N ‐ Nil ‐ C+O ‐ MMC
Velumurugan 833388B 5 9 M A 0.5 0.6 N N Nil ‐ C+O 4 MMC
W Mubaraq 573511C 6 8 M P 0.5 0.5 N N Nil ‐ C+O 2 MMC
Anubhav Kumar 611260C 9 14 M A 0.5 0.7 N N Nil Nil C+O 5 MMC
Chiku Kumar 736649C 4 ‐ M A 0.5 ‐ N ‐ R IV  ‐ C+O ‐ MMC
Dirija Anirudh 713786C 6 ‐ M P 0.6 ‐ N ‐ Nil ‐ C+O ‐ MMC
Githa's B 589608C 2 5 M A 0.4 0.5 N N Nil ‐ C+O 3 MMC
Harthi 019866B 3 17 F P 0.7 0.8 B/L mild N B/L IV Nil B/L reimplant 14 MMC
Jyothi Singh 694877C 1 ‐ F A ‐ ‐ L mod ‐ Nil ‐ C+O ‐ MMC
Kavitha's B 319860C 1 ‐ M A ‐ ‐ N ‐ ‐ ‐ C+O ‐ MMC
Md Muthalif 670925C 6 ‐ M P 0.5 ‐ B/L mild ‐ Nil ‐ C+O ‐ MMC
Mythili's B 6O5667C 1 3 F A 0.4 0.4 N N L II ‐ C+O 2 MMC
Merlin  191476B 5 21 F P 0.7 0.8 L mild L mild L V ‐ L reimplant 16 MMC
Nandana 603507C 6 8 F A 0.6 0.7 N N Nil ‐ Aug+ BNS 2 MMC
Noha Noman 654814C 4 ‐ M A 1.2 ‐ B/L mod ‐ Nil ‐ Aug ‐ MMC
Ponni's B 171030C 3 6 M A 0.4 0.5 N N Nil ‐ C+O 3 MMC
Priyanka 559622C 9 ‐ F P 0.9 ‐ B/L mod ‐ L V ‐ Aug + TUU ‐ MMC
Rkhi seal 638835C 8 ‐ M P 0.5 ‐ B/L mod ‐ L III C+O ‐ MMC
Rajath Hasan 628236C 8 10 M A 0.5 0.5 L mild N L I L I C+O 2 MMC
Rahul Kumar 688243C 11 12 M A 0.8 ‐ N N Nil ‐ C+O 1 MMC
Sanjana Mandal 328724C 12 15 F A 0.7 0.8 L mod N L V Nil L reimplant 3 MMC
Sushmitha 654753C 6 ‐ F A 0.6 ‐ N ‐ ‐ ‐ C+O ‐ MMC
Sai Shetty 403389B 9 11 F P 2.3 1.5 B/L gross B/L mild L V Nil Aug 2 MMC
Swetha 735584C 2 6 F P 0.5 0.6 N N R II Nil C+O 4 MMC
Thomas K Roy 626858C 2 3 M A 0.5 0.4 N N ‐ ‐ C+O 1 MMC
Vikas Kumar 760213C 8 ‐ M A 0.6 ‐ N ‐ Nil ‐ C+O ‐ MMC
Akash Sarkar 822076C 2 5 M P 0.7 0.5 B/L mod B/L mild R II R V Aug ‐ TUU 3 MMC
Abhishek 909893C 3 6 M A 0.4 0.4 N N R I Nil C+O 3 MMC
Dabbu Sharma 829868C 9 ‐ M A 0.6 ‐ N ‐ Nil ‐ C+O ‐ MMC
Dharshini 579419C 1 5 F P 0.4 0.5 B/L mod B/L mod R V ‐ C+O 4 MMC
Githa Devi's B 814056C 1 4 F A 0.4 0.4 R mild R mild Nil Nil C+O  3 MMC
Garima Jawar 872495C 3 5 F P 0.5 0.5 B/L gross B/L mod Nil ‐ Aug 2 MMC
Githa's B 589608C 1 4 M A 0.4 0.5 N N Nil ‐ C+O 3 MMC
Karan Kumar 861765C 9 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Lavanya 365223C 2 6 F A 0.5 0.5 N N Nil ‐ C+O 4 MMC
Ponnarasan 813488C 12 ‐ M A 0.7 ‐ N ‐ L I ‐ C+O ‐ MMC
Puja Kumari 946239C 6 ‐ F P 1.8 ‐ B/L mod ‐ B/L III ‐ C+O ‐ MMC
Rooba 847644C 5 18 F A 0.9 0.8 R mod, L gr B/L mild L IV ‐ C+O 13 MMC
Ambika's B 239457C 4 5 F P 0.6 0.6 B/L mild B/L mild B/L V ‐ C+O 1 MMC
Ayush Varma 090466D 2 4 M A 0.4 0.4 N N Nil ‐ C+O 2 MMC
Anupama Saha 985185C 1 3 F A 0.4 0.5 N N Nil ‐ C+O 2 MMC
Adithya Singh 953633C 6 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Jamuna Kumari 021608D 4 ‐ F A 0.4 ‐ N ‐ Nil ‐ C+O ‐ MMC
Jamsed Uddin 019336D 6 8 M P 0.5 0.6 L mod L mild Nil Nil C+O 2 MMC
Githa's B 034947C 5 8 M A 0.5 0.5 N N Nil ‐ C+O 3 MMC
Deepanjali 042456D 3 ‐ F P 0.4 ‐ N ‐ Nil ‐ C+O ‐ MMC
Doel Mukerjee 951215C 1 4 F P 1.3 0.6 B/L mod N Nil ‐ Aug 3 MMC
Yamini Podar 156163D 6 ‐ F P 1.5 ‐ B/L mod ‐ ‐ ‐ C+O ‐ MMC
Yasmin 160637D 3 14 F P 1.9 1.4 B/L gross B/L mod B/L V Nil B/L reimplant ‐ A11 MMC
Weebee Saha 987409C 0 1 F A 0.4 0.4 N N Nil ‐ C+O 1 MMC
V Mohonta 121664D 11 ‐ M P 0.4 ‐ B/L mild ‐ B/L IV ‐ C+O ‐ MMC
Vishnu Pandy 049848D 4 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Vineet V 036123D 6 ‐ M A 0.5 ‐ B/L mod ‐ Nil ‐ C+O ‐ MMC
Vignesh 522749B 7 12 M A 0.6 0.7 N N Nil ‐ C+O ‐ Aug + BND5 MMC
Usha's B 955364C 1 3 M P 1 0.5 B/L mild N Nil ‐ C+O 2 MMC
Tarani Sen 158360D 2 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Thomas Roy 626858C 2 ‐ M A 0.4 ‐ N ‐ ‐ ‐ C+O ‐ MMC
Snehalatha Das 068643C 8 10 F A 0.9 1 B/L mod B/L mod Nil ‐ C+O 2 MMC
Rajkumar 815795C 1 3 M A 0.4 0.5 N N Nil ‐ C+O 2 MMC
Raju S K 986509C 4 6 M P 0.4 0.5 B/L mod B/L mod B/L V B/L V C+O ‐ Aug  2 MMC
Puja maity 143766d 10 ‐ F A 1.6 ‐ B/L mild ‐ Nil ‐ C+O ‐ MMC
Pooja 337237C 6 8 F P 0.7 0.9 B/L mod B/L mild Nil Nil V ‐ Aug 2 MMC
Priya Prakash 031173D 12 14 F A 0.8 0.9 B/L mod B/L mod Nil ‐ C+ O  2 MMC
Nivetha 042595D 1 3 F A 0.4 0.4 B/L mild N R V ‐ C+O 2 MMC
Nithish 054893D 3 5 M P 1.9 0.8 B/L gross B/L mild B/L V ‐ V  2 MMC
Malay Bera 099149D 1 3 M A 0.4 0.3 N B/L mild  Nil ‐ C+O 2 MMC
Mukesh Kumar 024609D 8 ‐ M A 0.7 ‐ N ‐ Nil ‐ C+O ‐ MMC
L Ali Molla 962196C 8 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Kanman 896802C 2 4 M A 0.4 0.4 N N Nil ‐ C+O 2 MMC
Krishna Sumant 015891D 15 ‐ M A 0.6 ‐ N ‐ Nil ‐ C+O ‐ MMC
Sharunya 820083C 1 3 F A 0.4 0.4 N N Nil ‐ C+O 2 MMC
Swathi Shaw 634528C 3 5 F P 1.3 0.9 B/L mod L mild B/L IV L II Aug 2 MMC
Sudip Das 765698C 3 6 M P 0.4 0.5 N N Nil ‐ C+O ‐ Aug 3 MMC
Surya 927255C 5 7 M A 0.5 0.5 N N Nil ‐ C+O 2 MMC
Angel Mary 215143D 1 ‐ F A 0.5 0.5 B/L mod ‐ R V, L II ‐ C+O ‐ MMC
Amit Mathew 242207D 2 3 M A 0.6 0.6 N N ‐ ‐ C+O 1 MMC
Shahid Burnwal 426226C 3 6 M A 0.4 0.4 N N Nil ‐ C+O 3 MMC
Anshu Kujur 156830D 6 8 F P 0.5 0.5 L mod N B/L V Nil Aug 2 MMC
Debu Haldar 199189D 0 1 M A 0.4 0.4 N N L I ‐ C+O 1 MMC
Kabi Arasu 369214D 12 ‐ M A 0.7 ‐ B/L mod ‐ Nil ‐ C+O ‐ MMC
Latha's B 082427D 1 ‐ M P 0.4 ‐ N ‐ ‐ ‐ C+O ‐ MMC
Latha's B 244473D 0 1 M A 0.4 0.4 N N Nil ‐ C+O 1 MMC
Munna Kumar 321693D 12 13 M P 2.5 2.5 B/L mod B/L mod L I ‐ C+O 1 MMC
Md S Alam 338592D 6 7 M A 0.5 0.5 N N Nil ‐ C+O 1 MMC
Muzhu Mathi 263528D 2 ‐ F A 0.4 ‐ N ‐ B/L I ‐ C+O ‐ MMC
Niranjana 223447D 4 ‐ F A 0.5 ‐ N ‐ Nil ‐ C+O ‐ MMC
Pinki Kumari 312830D 1 ‐ F A 0.4 ‐ N ‐ Nil ‐ C+O ‐ MMC
Padmaja 243755D 4 5 F P 0.4 0.5 B/L mod ‐ R II, L II ‐ C+O 1 MMC
Prabavathi's B 235725C 6 7 M A 0.6 0.7 N N Nil ‐ Aug 1 MMC
Prasanna 217227D 4 5 M A 0.4 0.5 N N Nil ‐ C+O 1 MMC
Sathish 109534C 1 7 M P 1 0.6 B/L mod N Nil Nil V  6 MMC
Sumathi's B 405224C 3 4 M A 0.4 0.5 N N Nil ‐ C+O  1 MMC
Sushmitha S 213678D 8 10 F P 0.5 0.5 N B/L mod R III, L I ‐ C+O 2 MMC
Sayeta Bar 084800D 15 16 F P 0.6 0.7 B/L mod N Nil Nil Aug 1 MMC
Tanmay Sahu 315567D 14 15 F A 0.6 0.7 B/L mild  B/L mild Nil ‐ C+O 1 MMC
Yuvaraj 202545D 10 ‐ M A 0.8 ‐ B/L mod ‐ Nil ‐ C+O ‐ MMC
Vanitha' B 833388B 2 3 F P 2.2 0.7 B/L gross R mod R V Nil Aug 1 MMC
Suman Ghosh 758450B 6 ‐ F P 1 ‐ B/L mod ‐ R IV ‐ Aug ‐ MMC
Sahasrunam 750429C 1 3 M P 0.6 0.5 L mod N B/L V Nil Aug 2 MMC
Arpith Sumali  250591D 9 10 M A 0.6 0.6 N N ‐ ‐ C+O  1 MMC
Arnab Roy 268334C 2 8 M P 0.6 0.6 R mild,  R mild, B/L V Nil B/L reimplant 6 ARM
Rahul Roy 265127C 2 ‐ M P 0.6 ‐ L mod ‐ L III ‐ L reimplant ‐ ARM
Rahul Shaw 368462C 6 12 M P 0.7 0.9 B/L mod B/L mod L V Nil TUU 6 ARM
Ashwin Churchil 017020C 10 17 M A 0.6 0.9 B/L mild N Nil ‐ C+O 7 ARM
Hasinur Arza 420661C 3 4 M P 0.4 0.4 N N Nil ‐ C+O 1 ARM
Mark Sumi 602894B 2 3 M P 0.6 0.6 B/L mild B/L mild B/L V ‐ B/L reimplant+B1 ARM
Mala's Baby 602894B 5 10 F A 0.5 0.6 N N Nil ‐ C+O 5 ARM
Animesh Marji 178072C 2 7 M P 0.5 0.6 B/L mild L mild R V ‐ R reimplant 5 ARM
Utsaran Kundu 369399C 1 6 M A 0.3 0.6 L mild L mild Nil Nil C+O 5 ARM
Druv Kumar Dey 292298C 10 11 M A 0.7 0.7 N N B/L II ‐ C+O (App mitro)1 ARM
Jerry Mathew 385505C 5 8 M P 1 1.4 L mod L Mod L III ‐ Aug + BND 3 ARM
Karib 732410C 2 ‐ M A 0.6 ‐ N ‐ ‐ ‐ C+O ‐ ARM
Prathay Biswas 708775C 2 6 M P 0.5 0.5 N N R V, L V‐ B/L reimplant 4 ARM
Rahul 907972B 6 ‐ M A ‐ ‐ ‐ ‐ ‐ ‐ C+O ‐ ARM
Adrita Deb 743963C 3 7 M A 0.3 0.3 N N Nil ‐ C+O 4 ARM
Druvan Rajesh 643965C 3 ‐ M A 0.5 ‐ N ‐ ‐ ‐ C+O ‐ ARM
Parvatha Varthin 630420C 9 ‐ F A 0.6 ‐ ‐ ‐ ‐ ‐ C+O ‐ ARM
Sankchur Monal 535668C 10 ‐ M A 0.6 ‐ N ‐ Nil ‐ C+O ‐ ARM
Andreg Gomez 837408C 6 8 M A 0.6 0.6 N N ‐ ‐ C+O (App mitro)2 ARM
Abdulla 810009C 4 ‐ M A 0.5 ‐ L mod ‐ Nil ‐ Aug   ‐ ARM
Md Arafat 800903C 6 9 M P 0.9 0.8 L gross L mild L V Nil L reimplant 3 ARM
Harshvardhan S 133771D 9 12 M A 0.5 0.6 L mod L mod L V Nil Aug 3 ARM
Debnath Kisku 917493D 5 15 M P 0.8 1.3 L mod L mod L V Nil Aug 10 ARM
Soumya Biswas 117560D 4 6 M P 0.8 0.9 B/L mod B/L mild B/L V L I Aug 2 ARM
Shanmugam 031349D 1 3 M P 0.5 0.8 B/L mod B/L mild R IV R III Ves 2 ARM
Soumitha Manna779138B 4 11 F P 1.9 2.3 R mod  R mod B/L V Nil Aug 7 ARM
Sohail Ahmed 174767C 2 6 M A 0.6 ‐ B/L mod B/L mild ‐ ‐ C+O 4 ARM
Ajay 528468C 1 5 M A 0.6 0.6 L mild L mild B/L V ‐ B/L reimplant 4 ARM
Baby Sumandas 212907D 6 7 F A 0.6 0.6 R mild N L III ‐ Aug + BND 1 ARM
Latha's Baby 929249C 1 2 F A 0.4 0.4 N N ‐ ‐ C+O 1 ARM
Naveen Kumar 181426D 9 10 M A 0.6 0.8 R mod  N R V, L II ‐ Aug 1 ARM
Shindid Thamin 337203D 7 ‐ M A 0.6 ‐ B/L mild ‐ Nil ‐ C+O ‐ ARM
Soumitra C 405224C 7 8 F A 0.5 0.5 N ‐ Nil ‐ C+O 1 ARM
Abhishek Singh 346697D 8 10 M P 0.7 0.7 N N R III, L I Nil Aug 2 ARM
Souvit Das 307504C 3 ‐ F A 0.5 ‐ R mod  ‐ Nil ‐ C+O  ‐ SA+CRS
Kamesh Singh 237417C 6 8 M P 1.4 1.2 B/L gross B/L mild B/L V R I,  Aug 2 SA+CRS
Gajalakshmi 652963C 13 ‐ F A 0.8 ‐ L mod ‐ Nil ‐ C+O ‐ SA+CRS
Poornima Jana 607360C 12 ‐ M P 0.9 ‐ B/L gross ‐ L III ‐ Aug ‐ SA+CRS
Ramya 574993C 6 10 F P 0.5 0.6 B/L mod B/L mod R V Nil Aug 4 SA+CRS
Sujatha Mithra 598190C 4 5 F P 0.5 0.5 B/L mod N R V ‐ Aug 1 SA+CRS
Dhannraj S 083763D 3 ‐ M A 0.5 ‐ N ‐ Nil ‐ C+O (App mitro) ‐ SA+CRS
K Parmanik 991746C 11 ‐ F A 0.7 ‐ N ‐ Nil ‐ C+O ‐ SA+CRS
Suganthi's B 389601C 4 ‐ M A 0.5 ‐ B/L mild ‐ ‐ ‐ C+O ‐ SA+CRS
S Mandal 965407C 1 3 M A 0.4 0.5 N N Nil ‐ C+O 2 SA+CRS
Ashar Mathew 209764D 1 ‐ M A 0.5 ‐ N ‐ ‐ ‐ C+O ‐ SA+CRS
Nithya Hussain 339809D 5 ‐ F A 0.4 ‐ N ‐ Nil ‐ C+O (App mitro) ‐ SA+CRS
Shubham kumar 241208C 5 7 M A 0.4 0.5 N N ‐ ‐ C+O 2 CP
Nayeem 464509C 1 3 M P 0.4 0.5 L mild L mild L III ‐ L reimplant 2 CP
Poorni  142332B 10 15 F A 0.7 0.7 N N Nil ‐ C+O 5 CP
Sayan Dara 189372C 9 14 M A 0.6 0.5 N B/L mild Nil ‐ C+O 5 SCT
Kavitha's B 467911C 1 2 F A 0.4 0.6 L mild L mild ‐ ‐ C+O 1 SCT
Shubam K 241208C 4 6 M A 0.5 0.5 N N Nil ‐ C+O 2 ADEM
Smrithi B 596526C 11 ‐ F P 0.7 ‐ B/L mod ‐ Nil ‐ C+O ‐ CP
Subadeep B 454358C 10 13 M P 1.1 1.1 B/L mild B/L mod Nil ‐ C+O 3 Down's
Vamshi 646945C 7 11 M P 0.5 0.6 B/L gross B/L gross L V ‐ L reimplant 4 EDS
Kavia 776770C 7 9 F A 0.3 0.7 N L mild ‐ ‐ C+O 2 RP tumour
Keerthana 999142C 1 3 F P 2.5 1.6 B/L gross B/L mod B/L V ‐ Ves 2 CP
S Patak 991357C 7 8 F P 0.5 0.6 L mild L mild L II  ‐ C+O 1 CP
Mansi Choudury 197728D 2 4 F P 2.3 1.2 B/L gross B/L mild B/L V Nil Ves 2 Down's
Prabhavati 225413D 8 9 F A 0.5 0.5 N N Nil ‐ C+O 1 CP
Amshrah 264985C 3 8 M A 0.4 0.4 B/L mod B/L mild L I Nil C+O 5 NNNB
Silambarasan 715802A 10 25 M A 0.9 1.1 R gross R gross ‐ ‐ Aug 15 NNNB
Niranjan Kumar 537826C 2 4 M P 0.7 0.6 B/L gross B/L mild Nil ‐ Aug 2 NNNB
Akash Barua 708814C 8 9 M P 0.7 0.7 B/L mod B/L mod R V ‐ Aug 1 NNNB
Aishwarya 646216C 10 ‐ F P 0.9 ‐ B/L mod ‐ B/L IV ‐ C+O ‐ NNNB
Miher Das 792781C 1 3 M P 0.4 0.5 B/L mod  B/L mild B/L V B/L V Ves 2 NNNB
Abraham 921337C 13 15 M A 0.7 0.7 B/L mod N Nil ‐ C+O 2 NNNB
Abhishek P 133766D 2 ‐ M P 2.3 ‐ B/L gross ‐ R IV ‐ C+O ‐ NNNB
Anna Poorni 605667C 1 3 F A 0.4 0.4 N N L II ‐ C+O  2 NNNB
Manikandan 293012D 9 10 M P 0.8 0.8 B/L mod B/L mod B/L V ‐ B/L ureterostom1 NNNB
Naresh Kumar 142356C 3 10 M A 1.1 0.8 B/L mild B/L mild Nil ‐ C+O (App mitro)7 NNNB
Miriam 377569C 5 9 F A 0.8 0.7 L mod N R I, L V L I Aug 4 NNNB
